Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

ChristinaFleming366 Aug. 21 at 7:14 AM

$MRVL $COIN $TDOC $ADBE $JNJ Marvell benefits from AI networking and custom-chip demand, Coinbase benefits from crypto trading activity, Teladoc remains focused on digital healthcare, Adobe benefits from creative software and AI adoption, and Johnson & Johnson provides diversified healthcare exposure. I'm watching AI capex, crypto volumes, patient engagement, software growth, and healthcare demand.

0 · Reply

ForwardCurveCapital Aug. 21 at 6:33 AM

$JNJ 📊 GlobalUSAEuity ▼ 267.37 (-2.21%) Trend: Strong Uptrend 🚀 RSI (14): 65.44 (Neutral) MACD: Bullish, above signal line and rising 🟢 Volume: Normal ➖ 📌 Key Levels Resistance: 276.47 Support: 250.44 20-MA: 261.8 | 50-MA: 254.19 Educational content only. Not financial advice.

0 · Reply

Duncan74 Aug. 21 at 4:23 AM

$JNJ $SLS This is an absolute masterclass in corporate forensics, and it is exactly why the constant chart crying on this board is so pathetic. While the weak hands are inventing new theories, modeling the mathematical models with new assumptions, getting lost in abstract spreadsheets and sweating over intraday pennies and crying about market maker algorithms, our in-house biostatistician just laid out the exact paper trail of a classic Big Pharma buyout. Big Pharma deals don't happen by accident. They are hammered out in private closed-door J.P. Morgan meetings and trusted executive networks months before a database lock.

0 · Reply

SellasgpsCurativeBAT11 Aug. 21 at 3:06 AM

$JNJ $SLS Part 3. $SLS same 3 Top Institutional holders as $JNJ Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September 1, 2026. Very interesting Timeline of events. The latest update to J&J webpages on AML specifically are hard to ignore. So is the fact that the CEO who led AMBRX to a buyout by J&J in March 2024 (for a couple of Billion) was liking at least half a dozen or more of Dr. Stergiou's LinkedIn posts mid 2024-2025. Even with Stifel and all around, personal introductions between companies by a third party respected CEO that J&J already trusted can make a big difference. I truly believe $JNJ Deal Conversations began at November 2025 JP Morgan 1x1 conference. SELLAS Life Sciences Group participated in one-on-one (1x1) investor meetings at the J.P. Morgan U.S. Opportunities Forum on Wednesday, November 12, 2025, held at the Kimpton EPIC Hotel in Miami, FL, led by President and CEO Dr. Angelos Stergiou. ✌️🙏❤️‍🩹

1 · Reply

ElliottwaveForecast Aug. 21 at 1:20 AM

$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ

0 · Reply

Millionaire11 Aug. 20 at 8:26 PM

$CMPS Hey $JNJ we want minimum 5B. Anything less we are turning away.

0 · Reply

SellasgpsCurativeBAT11 Aug. 20 at 7:31 PM

$JNJ $SLS Part 2. JNJ is hunting for a $20B revenue gap to hit $50B in oncology by 2030, pouring cash into AML drugs with POOR durability (4.4 mo post-relapse survival). Meanwhile, $SLS where Big Pharma fails: • SLS009: 8.9 mo MOS (vs 2.5 mo historical) • GPS Curative vs. BAT 11 mOS. Meanwhile, the buyout puzzle pieces click: Leadership Lineup: Tom Cavanagh (leading us $JNJ acquisitions) overlapped directly with Katherine Bach Kalin at Celgene. Inside Bet: Katherine sits on the ras ŞSLS Board and bought 63,400 shares out of pocket (104,400 total). $$$ Muscle: With massive cash flow and pristine balance sheets, $JNJ can easily finance a multibillion dollar buyout. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Aug. 20 at 7:11 PM

$SLS $JNJ My # 1 Suitor for Sellas $JNJ is looking great. Shifting power dynamics as Big Pharma's H1 2026 revenue rankings are out! The Tier 1 Revenue Leaders • Johnson & Johnson ($49.40B): Retains the #1 spot globally through positioning across innovative medicine and medtech. ✌️🙏❤️‍🩹

0 · Reply

Ryuk Aug. 20 at 6:50 PM

$JNJ And it’s all gone. Puts up +300%.

0 · Reply

Prady Aug. 20 at 6:41 PM

$BSX $JNJ Johnson's buyout price would be north of 80+

1 · Reply

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD JNJ LLY MRK

Aug 10, 2026, 4:27 PM EDT - 10 days ago

Market Cap	658.89B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	24.96
Forward PE	23.35
Profit Margin	28.46%
Debt to Equity Ratio	0.44

Volume	6,475,800
Avg Vol	8,125,328
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	57%
Beta	0.24
Analysts	Strong Sell
Price Target	$275.42